Concurrently, the discovery of new biomarkers such as extracellular matrix proteins, angiogenic factors, p53-related protein kinase, circulating tumor cells, and microRNAs is redefining MM diagnosis and treatment [44–48]. The gene discussed is WEE1; the disease is Miyoshi myopathy.